Equinix Inc (EQIX)vsNovo Nordisk A/S (NVO)
EQIX
Equinix Inc
$1,089.15
+1.21%
REAL ESTATE · Cap: $105.71B
NVO
Novo Nordisk A/S
$42.96
-1.81%
HEALTHCARE · Cap: $194.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 3341% more annual revenue ($327.80B vs $9.53B). NVO leads profitability with a 37.2% profit margin vs 14.9%. NVO appears more attractively valued with a PEG of 3.19. NVO earns a higher WallStSmart Score of 73/100 (B).
EQIX
Buy54
out of 100
Grade: C-
NVO
Strong Buy73
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 24.3%
Earnings expanding 20.0% YoY
Attractively priced relative to earnings
Every $100 of equity generates 60 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Generating 12.0B in free cash flow
Areas to Watch
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EQIX
The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.1% demonstrates continued momentum.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : EQIX
The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 74.1x leaves little room for execution misses. Debt-to-equity of 1.63 is elevated, increasing financial risk.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
EQIX profiles as a value stock while NVO is a growth play — different risk/reward profiles.
EQIX carries more volatility with a beta of 1.00 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (73/100 vs 54/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Equinix Inc
REAL ESTATE · REIT - SPECIALTY · USA
Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other REIT - SPECIALTY Stocks
Want to dig deeper into these stocks?